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Introduction
Shigellosis, which is characterized by diarrhea and dysentery, 
is a worldwide human health problem caused by the Shigella 
group of bacteria (Niyogi, 2005). These bacteria produce a 
toxin, Shiga toxin, that is comprised of two components referred 
to as A and B, in which the A subunit is the enzymatically active 
toxin responsible for inactivation of the 28s ribosomal RNA, 
and the B subunit is required for binding and entry into target 
cells after transport across the polarized epithelial cells of the 
gut from their apical surface (for reviews see Johannes and 
Goud, 1998, 2000; O’Loughlin and Robins-Browne, 2001; 
Sandvig and van Deurs, 2002; Spooner et al., 2006). How Shiga 
toxin is able to enter and intoxicate cells is of great medical 
interest; therefore, this has been studied extensively (Sandvig 
et al., 1992; Mallard et al., 1998, 2002). The Shiga toxin B sub-
unit (STxB) binds to Gb3, a neutral glycosphingolipid at the 
surface of target cells in the gut vasculature, as well as in the 
kidney and brain and is then internalized by a combination of 
  clathrin-  mediated and clathrin-  independent endocytic pathways 
(Sandvig et al., 1989; Nichols et al., 2001; for review see 
O’Loughlin and Robins-Browne, 2001).
Once internalized, Shiga toxin is then transported directly 
from early and recycling endosomes to the trans-Golgi net-
work (Mallard et al., 1998; Bonifacino and Rojas, 2006). This 
pathway is dependent on the function of clathrin and dynamin 
(  Lauvrak et al., 2004), the small GTP-binding protein Rab6 and 
its effector proteins, the lipid phosphatase OCRL1, a defi  ned set 
of SNAREs (Mallard et al., 2002; Monier et al., 2002; Tai et al., 
2004; Choudhury et al., 2005; Hyvola et al., 2006), and a sec-
ond GTP-binding protein Arl1 and its effector golgin-97 (Lu 
et al., 2004). From the TGN, the toxin is then transported by a 
retrograde pathway dependent on Rab6 through the Golgi appa-
ratus to the ER (Sandvig et al., 1992; White et al., 1999), where 
the toxin A subunit enters the cytoplasm most likely by retro-
translocation (for review see Sandvig and van Deurs, 2002).
Despite the multistep nature of the Shiga toxin uptake 
pathway, only a single Rab GTP-binding protein, Rab6, has 
been shown to play any role in its transport (Girod et al., 1999; 
White et al., 1999; Mallard et al., 2002). Because each mem-
brane traffi  cking step is thought to involve a discrete set of Rabs 
(Zerial and McBride, 2001), it seems likely that additional Rabs 
are involved in Shiga toxin uptake. To further defi  ne the   pathway 
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ab family guanosine triphosphatases (GTPases) 
together with their regulators deﬁ  ne speciﬁ  c path-
ways of membrane trafﬁ  c within eukaryotic cells. In 
this study, we have investigated which Rab GTPase-
activating proteins (GAPs) can interfere with the traf-
ﬁ  cking of Shiga toxin from the cell surface to the Golgi 
apparatus and studied transport of the epidermal growth 
factor (EGF) from the cell surface to endosomes. This screen 
identiﬁ  es 6 (EVI5, RN-tre/USP6NL, TBC1D10A–C, and 
TBC1D17) of 39 predicted human Rab GAPs as speciﬁ  c 
regulators of Shiga toxin but not EGF uptake. We show 
that Rab43 is the target of RN-tre and is required for 
Shiga toxin uptake. In contrast, RabGAP-5, a Rab5 GAP, 
was unique among the GAPs tested and reduced the 
  uptake of EGF but not Shiga toxin. These results suggest 
that Shiga toxin trafﬁ   cking to the Golgi is a multistep 
process controlled by several Rab GAPs and their target 
Rabs and that this process is discrete from ligand-  induced 
EGF receptor trafﬁ  cking.
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of Shiga toxin transport between the cell surface and the Golgi 
apparatus, we have focused on the identifi  cation of Rab GTPase-
activating proteins (GAPs) that interfere with this step. Rab 
GAPs are characterized by a conserved catalytic domain, the 
TBC (Tre2/Bub2/Cdc16) domain (Strom et al., 1993; Albert 
and Gallwitz, 1999; Albert et al., 1999), that promotes GTP 
hydrolysis by a dual arginine/glutamine fi  nger catalytic mecha-
nism related to the arginine fi  nger mechanism of Ras GAPs 
(Ahmadian et al., 1997, 1999; Rak et al., 2000; Pan et al., 2006). 
As we have shown previously in the case of Rab5 (Haas et al., 
2005), Rab GAPs can be used to specifi  cally inactivate the en-
dogenous pool of a Rab and, thus, interfere with the process this 
Rab is involved in. Nonspecifi  c effects of Rab GAP expression 
can easily be discriminated from the specifi  c effects of Rab in-
activation by use of an inactive point mutant in which the cata-
lytic arginine residue is replaced by alanine (Haas et al., 2005).
Because the human genome encodes >60 Rabs and at 
least 39 TBC domain–containing proteins, the identifi  cation of 
specifi  c Rab–Rab GAP pairs is not a trivial task (Zerial and 
McBride, 2001; Haas et al., 2005). In the present study, we have 
screened for human Rab GAPs that specifi  cally inhibit the trans-
port of Shiga toxin to the Golgi apparatus and do not have any 
effects of the uptake of EGF and its receptor. By combining this 
functional assay with biochemical analysis of GTP hydrolysis, 
we are able to identify discrete pairs of Rabs and Rab GAPs 
acting in the Shiga toxin and EGF transport pathways.
Results
Molecular requirements for Shiga toxin 
and EGF trafﬁ  cking
To investigate the requirements for specifi  c Rab GAPs in the 
traffi  cking of Shiga toxin to the Golgi but not the endocytic up-
take of growth factors such as EGF, it was necessary to establish 
conditions for the uptake of these two ligands. Fluorescently 
labeled STxB and EGF were bound to the cell surface on ice, and, 
after washing to remove excess toxin, cells were warmed, and 
uptake of the two ligands was followed by immunofl  uorescence 
microscopy (Fig. 1). Initially, both ligands were present on the 
cell surface (0 min) and became internalized into small punctate 
structures at 10–20 min (Fig. 1). After this, the two markers 
separated, and Shiga toxin accumulated in a perinuclear com-
partment from 30 to 60 min that was previously shown to cor-
respond to the trans-Golgi network and Golgi stacks (Sandvig 
et al., 1992; Mallard et al., 1998), whereas, as expected, EGF 
remained in punctate endosomal structures (Fig. 1). Interest-
ingly, although both ligands have been reported to be taken up 
by clathrin-dependent pathways (Sandvig et al., 1989; Nichols 
et al., 2001), the kinetics of uptake are clearly different, indi-
cating that there may be some differences in the mechanistic de-
tails such as the requirement for Rab GTPases. Therefore, for 
further experiments, it was decided to take a 60-min uptake of 
Shiga toxin to measure the effi  ciency of its transport to the 
Golgi and a 30-min uptake of EGF to measure its uptake into 
early endosomes.
The uptake of Shiga toxin has previously been shown to 
be Rab6 dependent (White et al., 1999; Mallard et al., 2002), 
whereas that of EGF should be Rab6 independent. To verify 
this, the uptake of these two ligands was followed in cells 
depleted of Rab6 (Fig. 2). Immunofl  uorescence analysis showed 
that Rab6 was effi  ciently depleted after 72 h of treatment with 
specifi  c siRNA duplexes (Fig. 2 A). Importantly, the Rab6 
effector protein Bicaudal-D1 was redistributed from the Golgi 
to the cytoplasm (Fig. 2 A), indicating that Rab6 function was 
impaired. Compared with control cells, Rab6 depletion resulted 
in a decrease in the amount of Shiga toxin reaching the Golgi 
apparatus after 60 min of uptake (Fig. 2 B). Under these condi-
tions, the Golgi marker TGN46 was unaltered, suggesting that 
this decrease is not caused by disruption of the Golgi appara-
tus. In contrast, no obvious differences could be seen in the up-
take of EGF when comparing control and Rab6-depleted cells 
(Fig. 2 B). Expression of a dominant-active mutant of Rab5 
resulted in the formation of enlarged early endocytic structures 
coated with the Rab5 effector EEA1 as expected (Stenmark 
et al., 1994). These structures accumulated both EGF and Shiga 
toxin, suggesting that these ligands traffi  c via a Rab5-dependent 
pathway through early endosomes (Fig. 2 C).
Figure 1.  Comparison of the Shiga toxin and EGF uptake pathways. Fluor-
escently labeled STxB (red) and EGF (green) were bound on ice to the sur-
face of HeLa cells starved of serum overnight. Excess ligands were washed 
away, and the cells were incubated in complete growth medium at 37°C 
for the times indicated in the ﬁ  gure. The cells were then ﬁ  xed and mounted 
without further processing. DNA was stained with DAPI (blue). Bar, 10 μm.RAB GAPS REGULATING SHIGA TOXIN TRANSPORT • FUCHS ET AL. 1135
Therefore, EGF takes a Rab6-independent traffi  cking route, 
whereas Shiga toxin transport to the Golgi is Rab6 dependent. 
Based on these fi  ndings, a Rab6 GAP would be expected to block 
Shiga toxin but not EGF uptake, whereas a Rab5 GAP might 
block both. Because specifi  c GAPs for both Rab5 and Rab6 
have previously been identifi  ed (Cuif et al., 1999; Lanzetti et al., 
2000; Haas et al., 2005), these predictions were tested.
Shiga toxin trafﬁ  cking to the Golgi 
apparatus is independent 
of TBC1D11/GAPCenA
It has previously been reported that TBC1D11/GAPCenA is the 
GAP for Rab6 (Cuif et al., 1999), and, thus, this was tested for 
its ability to block the traffi  cking of Shiga toxin to the Golgi 
 apparatus. Surprisingly, the expression of TBC1D11/GAPCenA 
had no obvious effect on the transport of Shiga toxin to the 
Golgi apparatus (Fig. 3 A) or on the ability of Rab6 or the 
Rab6-dependent effector Bicaudal-D1 (Matanis et al., 2002; Short 
et al., 2002) to target to Golgi membranes (Fig. 3 B). Therefore, 
TBC1D11/GAPCenA was further investigated to fi  nd out whether 
it has the biochemical properties expected of a Rab6 GAP.
Confi   rming previous fi   ndings (Cuif et al., 1999), a 
C-terminal fragment of TBC1D11/GAPCenA was identifi  ed when 
Rab6 was screened against a yeast two-hybrid cDNA library 
(unpublished data). However, this fragment corresponding to a 
predicted coiled-coil region adjacent to the GAP domain does 
not show a specifi  c interaction with Rab6 and binds to human 
Rabs of many different subfamilies when tested against a repre-
sentative collection of human Rabs (Fig. 3 C). When full-length 
TBC1D11/GAPCenA was tested, it showed a strong interaction 
with Rab4, a weaker interaction with Rab11, and only a very 
weak interaction with Rab6 (Fig. 3 C). A more detailed analysis 
in which multiple deletion constructs of TBC1D11/GAPCenA 
were tested revealed that regions N and C terminal to the core 
Figure 2.  Shiga toxin but not EGF uptake is Rab6 depen-
dent. (A and B) HeLa cells were treated with control or Rab6 
siRNA for 72 h and were either ﬁ  xed and stained with anti-
bodies to either Rab6 or Bicaudal-D1 (red) and TGN46 
(green; A) or used for Shiga toxin (red) and EGF (green) uptake 
assays and costained for TGN46 (green) or EEA1 (red; B). 
(C) HeLa cells transfected with the GFP-tagged Rab5
Q79A 
dominant-active mutant (green) for 24 h were used for Shiga 
toxin and EGF (red) uptake assays or were stained for EEA1 
and transferrin receptor (red). DNA was stained with DAPI 
(blue). Bar, 10 μm.JCB • VOLUME 177 • NUMBER 6 • 2007  1136
TBC domain contribute to the recognition of specifi  c Rabs 
(Fig. S1, available at http://www.jcb.org/cgi/content/full/jcb
.200612068/DC1). This suggested that Rab6 might not be the 
target for TBC1D11/GAPCenA after all, and biochemical as-
says were performed to test this. In agreement with the yeast 
two-hybrid data, TBC1D11/GAPCenA had strong GAP activity 
toward Rab4 and a lesser activity toward Rab11 (Fig. 3 D). Only 
very weak activity was detected toward Rab2 and 14 (Fig. 3 D), 
which fall into the same Rab subfamily as Rab4 and 11, showing 
that TBC1D11/GAPCenA can discriminate between closely 
related Rabs. No activity could be detected toward Rab6 or any of 
the other Rabs tested (Fig. 3 D), although all were loaded with 
GTP to the same extent. It was previously suggested that Rab6 
has to be prenylated to be an effi  cient substrate for TBC1D11/
GAPCenA, and this was tested. However, no GAP activity could 
be seen when prenylated Rab6 purifi  ed from insect cells was used 
(Fig. 3 D, Rab6
Sf9). It should also be noted that Rab4 was pre-
pared in bacteria and was therefore not prenylated but was still 
an excellent substrate for TBC1D11/GAPCenA. These data 
show that TBC1D11/GAPCenA is a GAP for Rab4 but not 
Rab6 and that it does not alter the traffi  cking of Shiga toxin to 
the Golgi apparatus.
A screen for Rab GAPs altering Shiga 
toxin trafﬁ  cking
An unbiased approach was taken to identify which Rab GAPs 
act on the Shiga toxin transport pathway. Cells expressing the 
various predicted human Rab GAPs were tested blindly for their 
ability to transport Shiga toxin to the Golgi apparatus and EGF 
to early endosomes (unpublished data). Candidate positives from 
this fi  rst round of screening were then retested, comparing the 
effects of the wild-type GAP to that of a catalytically inactive 
point mutant. In this screen, 6 of 39 predicted GAPs showed 
catalytic activity–dependent effects on Shiga toxin traffi  cking to 
the Golgi apparatus (Table I and Fig. 4, A and B). In contrast, in 
a parallel screen, only RabGAP-5 was able to block the uptake 
of EGF to early endosomes (Table I and Fig. 5, A and B).
To be sure that the lack of a Golgi signal for Shiga toxin 
after 60 min of uptake was not simply a result of disruption of 
the Golgi, the integrity of this organelle was tested using markers 
for the cis- and trans-Golgi compartments (Fig. S2, available 
at http://www.jcb.org/cgi/content/full/jcb.200612068/DC1). 
This resulted in the elimination of GAPs such as TBC1D22A 
and 22B in which the Golgi was fragmented, and Shiga toxin 
was found to localize to these fragments (Fig. S2 and not 
 depicted). In the case of TBC1D14, although the Golgi was frag-
mented, Shiga toxin did not localize to these Golgi fragments, 
indicating there was a block in transport. However, these effects 
were not caused by Rab inactivation because the inactive point 
mutant gave a similar phenotype (Fig. 4, A and B; and Fig. S2). 
Interestingly, there was no effect on the traffi  cking of EGF, 
suggesting that TBC1D14 is not disrupting early endosome 
function. In contrast, RN-tre, although fragmenting the Golgi, 
caused a block of Shiga toxin in more peripheral structures 
discrete from the Golgi dependent on its catalytic activity; 
therefore, this was counted as a positive (Figs. 4 and S2, and 
not depicted).
The ability of candidate positives to protect cells against 
the cytotoxic effects of complete Shiga-like toxin 1 was then 
tested (Fig. 4 C). This assay measures protein synthesis, which 
is inhibited if Shiga toxin can reach the ER and enter the cyto-
plasm and, therefore, is a more stringent measure of Shiga toxin 
traffi  cking than fl  uorescent assays (Spooner et al., 2004). This 
approach showed that EVI5, RN-tre, and TBC1D17 protect 
against Shiga-like toxin 1 between 1.87- and 3.35-fold, whereas 
RabGAP-5 with a fold protection of 1.07 could not (Fig. 4 C). 
Figure 3.  TBC1D11/GAPCenA is a GAP for 
Rab4 and does not block Shiga toxin uptake. 
(A) HeLa cells transfected with GFP-tagged 
TBC1D11/GAPCenA (green) were used for 
Shiga toxin uptake assays (red). (B) The ability 
of Rab6 and Bicaudal-D1 (red) to localize 
to the Golgi was tested in cells expressing 
GFP-tagged TBC1D11/GAPCenA (green). 
(C) A schematic of TBC1D11/GAPCenA shows 
the putative phosphotyrosine-binding domain 
(PTB; blue), the TBC domain (red), and a C-
  terminal coiled-coil region (green). Full-length 
TBC1D11/GAPCenA and the C-terminal 
coiled-coil region identiﬁ  ed by unbiased yeast 
two-hybrid library screen prey constructs were 
tested against the human Rabome bait con-
struct library as described in Materials and 
methods. All conditions showed equal growth 
on nonselective media; the ability to grow on 
the selective media shown in the ﬁ  gure is an 
indicator of an interaction between the bait 
and prey. (D) GAP assays were performed 
  using 0.5 pmol of recombinant TBC1D11/
GAPCenA (closed bars) or a buffer control 
(open bars) and 100 pmol of the Rabs indi-
cated in the ﬁ  gure. Two preparations of Rab6 
were used: one from bacteria (Rab6), and the 
other a prenylated preparation produced in in-
sect cells (Rab6
Sf9). Error bars represent SD. 
Bar, 10 μm.RAB GAPS REGULATING SHIGA TOXIN TRANSPORT • FUCHS ET AL. 1137
The TBC1D10 family of GAPs showed variable extents of 
protection, and, therefore, it is unclear whether these represent 
specifi  c positives with this assay. Interestingly, none of the pos-
itive GAPs were able to cause the release of the Rab6 effector 
Bicaudal-D1 from Golgi membranes (Fig. S3, available at http://
www.jcb.org/cgi/content/full/jcb.200612068/DC1), even those 
that showed some effects on Golgi morphology (Fig. S2). This 
suggests that they do not act on Rab6. The traffi  cking pathway 
of Shiga toxin from the cell surface to the Golgi is therefore de-
fi  ned by the following Rab GAPs: EVI-5, RN-tre, the TBC1D10 
family, and TBC1D17. 
Different GAPs deﬁ  ne the uptake routes 
for EGF and Shiga toxin
Although RN-tre was initially suggested to act on Rab5 and, 
thus, the EGF uptake pathway (Lanzetti et al., 2000), more 
recently, another GAP, RabGAP-5, has also been proposed to 
fulfi  ll this function (Haas et al., 2005). To clarify this point, the 
effects of RN-tre and RabGAP-5 on the uptake of EGF and 
Shiga toxin were directly compared (Fig. 6). RabGAP-5 was 
able to block the uptake of EGF (Fig. 6 A) and displace the Rab5-
dependent effector molecule EEA1 from endosomes (Fig. 6 B) 
but had no effect on the uptake of Shiga toxin (Fig. 6 C). RN-tre 
or a catalytically inactivate point mutant of RabGAP-5 did not 
show these effects on EGF uptake (Fig. 6, A and B). In contrast, 
RN-tre was able to block the transport of Shiga toxin to the 
Golgi apparatus (Fig. 6 C) and caused partial fragmentation 
of the Golgi apparatus (Figs. 6 D and S2), which is consistent 
with previous observations that its target, Rab43, is localized 
to this organelle (Haas et al., 2005). Note that Rab43 was re-
ferred to as Rab41 in a previous study (Haas et al., 2005), which 
is consistent with the naming in mice; however, the gene no-
menclature has now been clarifi  ed so that this gene is called 
Rab43 in both the mouse and human. RabGAP-5 or a catalyti-
cally inactive point mutant of RN-tre did not show these effects 
(Fig. 6, C and D). In some cells expressing very high levels of 
RN-tre, the uptake of EGF was blocked, but further investiga-
tion revealed that these cells lack detectable EGF receptor on 
the cell surface (unpublished data). Therefore, the apparent 
uptake block is caused by a lack of EGF binding and not by a 
defect in endocytosis of the receptor–ligand complex. One 
explanation for the reduced level of EGF receptor at the cell 
surface could be the disrupted Golgi apparatus seen in RN-tre–
expressing cells (Figs. 6 D and S2). Thus, any effects of RN-tre 
on EGF receptor uptake would appear to be indirect.
Identiﬁ  cation and veriﬁ  cation 
of target Rabs
To identify the target Rabs of the positive GAPs identifi  ed thus 
far, they were tested for their ability to accelerate GTP hydrolysis 
by a specifi  c Rab in biochemical assays with a wide set of human 
Rabs (Fig. 7). These data clearly show that of the Rabs tested, the 
Table I. Effects of human TBC domain–containing proteins on Shiga toxin transport
Rab GAP Wild-type TBC domain Catalytically inactive TBC domain
Target 
Rab
STxB GAP 
localization
EGF Golgi STxB GAP 
localization
EGF
EVI-5 35 Vesicular Cytosolic Early 
endosomes
a
Intact Golgi Tubules, 
cytosolic
ND
RN-tre 
 (USP6NL)
41 Cell surface 
vesicular
Cell surface Early 
endosomes
a
Fragmented Golgi Cell surface ND
RabGAP-5 
 (RUTBC3)
5A-C Golgi Cytosolic Cell surface Intact Golgi
b Cytosolic Early 
endosomes
TBC1D10A ND Vesicular 
Golgi
Cell surface Early 
endosomes
a
Intact Golgi Cell surface ND
TBC1D10B 22a/31 Vesicular Cell surface Early 
endosomes
Intact Golgi Cell surface ND
TBC1D10C ND Vesicular Filopodia, 
cell surface
Early 
endosomes
Intact Golgi Cell surface ND
TBC1D11 
 (GAPCenA)
4>11 Golgi Cytosolic Early 
endosomes
Intact ND Cytosolic ND
TBC1D14 ND Recycling 
endosomes
Recycling 
endosomes
Early 
endosomes
Fragmented Recycling 
endosomes
Recycling 
endosomes
ND
TBC1D17 21 Vesicular Cytosolic Early 
endosomes
Intact Golgi Cytosolic ND
TBC1D22A 33A-B
c Golgi 
fragments
Cytosolic, 
nuclear
Early 
endosomes
Fragmented Golgi Cytosolic/
nuclear
ND
TBC1D22B 33A-B
c Golgi 
fragments
Cytosolic, 
nuclear
Early 
endosomes
Fragmented Golgi Cytosolic/
nuclear
ND
HeLa cells were transfected for 24 h with GFP-tagged wild-type or catalytically inactive Rab GAPs. These cells were then used for SSTxB or EGF uptake assays, and 
the uptake of STxB and EGF were scored at 1 h or 30 min, respectively. A 0-min time point was also taken to verify that both STxB and EGF were bound to the cell 
surface with equal efﬁ  ciency for all conditions. Localization of the GFP-tagged Rab GAPs was also scored.
aSome highly expressing cells failed to bind EGF at the zero time point, indicating a potential defect in the trafﬁ  cking of EGF receptor to the cell surface. However, 
the majority of cells bound and took up EGF as normal.
bThe RabGAP-5 GAP domain was used for this experiment.
cTBC1D22 family GAPs have previously been shown to act on Rab33 (Pan et al., 2006).JCB • VOLUME 177 • NUMBER 6 • 2007  1138
Rab5a-c subfamily are substrates for RabGAP-5, whereas Rn-tre 
acts on Rab43. EVI5 showed strong and specifi  c activity toward 
Rab35 (>1,200 pmol/h of hydrolyzed GTP), but Rab35 was 
found to be weakly (sixfold less) activated with several of the 
GAPs tested here, suggesting that this may be a false positive hit. 
The substrates of TBC1D10B and TBC1D17 cannot be identifi  ed 
with certainty from the data obtained. Careful analysis of the pat-
tern of GTP hydrolysis suggests that TBC1D10B might act on 
Rab22a/Rab31, which fall into the same branch of the Rab5 sub-
family, whereas TBC1D17 might be a GAP for Rab21 (Fig. 7).
Figure 4.  A subset of human Rab GAPs inﬂ  uence Shiga toxin transport. 
(A) Shiga toxin uptake assays were performed on HeLa cells transfected 
with a library of wild-type human Rab GAPs. Those Rab GAPs showing 
a block in Shiga toxin uptake were retested as catalytically inactive RA 
mutants. To measure the extent of Shiga toxin uptake, HeLa cells were trans-
fected with the GFP-tagged wild-type and catalytically inactive mutant 
GAPs indicated in the ﬁ  gure. These cells were then ﬁ  xed and stained for a 
Golgi marker. The percentage of untransfected and transfected cells in 
which STxB had reached the Golgi was counted for each condition, and 
the speciﬁ  c reduction in Shiga toxin transport was calculated by subtracting 
these two ﬁ  gures (transfected − untransfected cells). These numbers are 
plotted on the bar graph. The dotted red line indicates the cut-off chosen 
for consideration as a positive. Asterisks indicate that transport was the 
same as in control cells. (B) Images of the Rab GAPs showing a catalytic 
activity–dependent block or reduction in Shiga toxin uptake after 60 min. 
Shiga toxin is in red, transfected Rab GAPs are in green, and DNA is 
stained blue. (C) Cytotoxicity assays were performed using the Rab GAPs 
listed in the ﬁ  gure. The IC50 of Shiga-like toxin 1 was measured in cells ex-
pressing either the wild type (WT) or the catalytically inactive (RA) mutant 
GAPs. These values were then corrected for transfection efﬁ  ciency averag-
ing 13.9–18.7%. An increase in the IC50 for wild type compared with RA 
GAPs indicates reduced cytotoxicity, and this is plotted in the graph as the 
fold protection, with 1 (red dotted line) corresponding to no protection 
(n ≥ 3). The corrected IC50 values for each condition are shown above each 
column, and the IC50 of empty vector–transfected control cells was 3.5 ng/ml. 
Error bars represent SD. Bar, 10 μm.
Figure 5.  Rab GAPs altering Shiga toxin transport do not prevent EGF 
uptake. (A) EGF uptake assays were performed on HeLa cells transfected 
with a library of wild-type human Rab GAPs listed in the ﬁ  gure. The number 
of cells binding and then taking up EGF was counted for each condition. 
The graph shows cells either failing to bind (open bars) or taking up (closed 
bars) EGF. (B) EGF uptake assays were performed on HeLa cells trans-
fected with the Rab GAPs capable of blocking Shiga toxin uptake and 
RabGAP-5. The initially bound EGF at 0 min of transport and the extent of 
EGF transport at 30 min are shown. EGF is in red, transfected Rab GAPs 
are in green, and DNA is stained blue. Bar, 10 μm.RAB GAPS REGULATING SHIGA TOXIN TRANSPORT • FUCHS ET AL. 1139
If the effects of RabGAP-5 on EGF uptake are mediated 
through Rab5 and those of RN-tre on Shiga toxin transport are 
mediated through Rab43, cells depleted of these Rabs should 
display a similar defect to that seen on overexpressing the re-
spective GAP because both conditions reduce the pool of active 
Rab. In line with this prediction, EEA1 fails to localize to endo-
somes, and there is a strong reduction in EGF uptake in cells 
depleted of Rab5 (Fig. 8 A). These cells are still able to trans-
port Shiga toxin to the Golgi apparatus similar to the control 
cells (Fig. 8 B). In contrast, the Golgi is disorganized, and there 
is a strong reduction in the transport of Shiga toxin to the Golgi 
in cells depleted of Rab43 (Fig. 8 C). However, these cells are 
still able take up EGF similar to the control cells (Fig. 8 D). 
Consistent with a role for RN-tre and Rab43 in the transport of 
Shiga toxin to the Golgi apparatus, Rab43 localized to this or-
ganelle and showed a staining pattern most similar to the trans-
Golgi marker TGN46 (Fig. 8 E). Rab43 showed no overlap with 
the early endosome marker EEA1 (Fig. 8 E), suggesting that 
it does not function at early endosomes. Finally, although the 
siRNA duplexes used were effi  cient in targeting the appropriate 
Rab (Fig. S5 A, available at http://www.jcb.org/cgi/content/full/
jcb.200612068/DC1), the depletion of Rab21, 22a, 31, and 35 
had no clear effects on either Shiga toxin or EGF uptake (un-
published data), and it is therefore unclear whether these Rabs 
are the targets of the TBC1D10 family of GAPs, TBC1D17, and 
EVI5. Thus, it will require further investigation to validate the 
targets of these GAPs.
Together, these observations support two important con-
clusions. First, RN-tre specifi  cally blocks the Rab43-dependent 
traffi  cking of Shiga toxin to the trans-Golgi apparatus, and EGF 
does not follow this pathway. Second, RabGAP-5 specifi  cally 
blocks the Rab5-dependent traffi  cking of EGF through early 
endosomes, and Shiga toxin does not follow this pathway. There-
fore, these two Rab GAPs and their target Rabs defi  ne specifi  c 
traffi  cking routes for Shiga toxin and EGF.
Discussion
Trafﬁ  cking pathways can be delineated 
by Rabs and their GAPs
In this study, we have presented evidence that different sets of 
Rab GAPs and their target Rabs control specifi  c endocytic traf-
fi  cking pathways. These results suggest that although the traf-
fi  cking of Shiga toxin from the cell surface to the Golgi is a 
Figure 6.  Discrete Rab GAPs deﬁ  ne the Shiga toxin and EGF uptake pathways. (A and B) HeLa cells were transfected for 24 h with RabGAP-5, the catalyti-
cally inactive RabGAP-5
R165A mutant, or RN-tre. (A) EGF uptake assays were performed, and the initially bound EGF at 0 min of transport and extent of 
EGF transport at 30 min are shown in the ﬁ  gure. EGF is in red, and transfected Rab GAPs are in green. (B) The cells were ﬁ  xed and stained for the trans-
fected Rab GAPs (green) and EEA1 (red). (C and D) HeLa cells were transfected for 24 h with RN-tre, the catalytically inactive RN-tre
R150A mutant, or Rab-
GAP-5. (C) Shiga toxin uptake assays were performed, and the initially bound Shiga toxin at 0 min of transport and extent of STxB transport to the Golgi 
at 60 min are shown. STxB is in red, and transfected Rab GAPs are in green. (D) The cells were ﬁ  xed and stained for the transfected Rab GAPs (green) 
and GM130 (red). DNA is stained blue in all panels. Bar, 10 μm.JCB • VOLUME 177 • NUMBER 6 • 2007  1140
multistep process dependent on at least six different Rabs and 
Rab GAPs, EGF traffi  cking depends only on the action of Rab5 
and RabGAP-5. There has been some controversy in the litera-
ture concerning the relative importance of RN-tre and RabGAP-5 
as regulators for Rab5 and their involvement in the uptake of 
endocytosed ligands (Lanzetti et al., 2000; Haas et al., 2005). 
However, the results presented here clearly show that although 
both of these GAPs are involved in the traffi  cking of endo-
cytosed ligands, they act on discrete traffi  cking pathways. 
One   explanation for the differential sensitivity of EGF receptor 
traffi  cking to RN-tre could relate to the conditions and cell lines 
used. With low doses of EGF, the EGF receptor is almost en-
tirely transported via the clathrin-dependent pathway, whereas 
at higher or saturating doses, it spills over into the clathrin-
independent pathway (Sigismund et al., 2005). Thus, with satu-
rating amounts of EGF, RN-tre would be able to prevent trans port 
of the pool of EGF receptor entering via the clathrin-indepen-
dent pathway. However, our data suggest that this would be a 
Rab5-independent and Rab43-dependent pathway.
The role of Rab6 in the Shiga toxin 
trafﬁ  cking pathway
None of the GAPs capable of blocking Shiga toxin transport was 
able to cause the release of Bicaudal-D1 from the Golgi to the 
cytoplasm (Fig. S3), and this indicates that they do not act on 
Rab6. Why the Rab6 GAP was not found in the screen is unclear, 
but because the depletion of Rab6 reduces Shiga toxin transport 
to the Golgi (Fig. 2; Del Nery et al., 2006), this has to be viewed 
as a false negative. There is evidence that some TBC domain 
proteins form heterodimeric complexes (Pereira et al., 2001) and 
that this is necessary for their activity. If this is the case for the 
Rab6 GAP, it could have been missed in the current screen.
What is clear is that TBC1D11/GAPCenA is unlikely to 
be the GAP for Rab6. It displays robust biochemical activity to-
ward Rab4 but not Rab6 and has none of the cell biological 
properties expected for a Rab6 GAP. It cannot block Shiga toxin 
traffi  cking or cause release of the Rab6 effector Bicaudal-D1 
from the Golgi. Therefore, at this time, the identity of the Rab6 
GAP remains mysterious and will require further investigation.
Some cautions on the use of dominant-
active Rabs
Some of the results presented here suggest that there are prob-
lems with the use of dominant-active GTP-locked Rabs. Al-
though the expression of dominant-active Rab5
Q79A results in 
the trapping of Shiga toxin in an early endocytic compartment, 
indicating its transport is Rab5 dependent, this interpretation 
is not supported by the use of specifi  c Rab GAPs. Although 
RabGAP-5 does block EGF and transferrin traffi  cking (Haas 
et al., 2005), it has no effect on the transport of Shiga toxin to the 
Golgi (Fig. 6). This suggests that although Shiga toxin traffi  ck-
ing is normally Rab5 independent, when dominant-active Rab5 
is expressed, it becomes trapped in the enlarged early endocytic 
compartment created under these conditions (Stenmark et al., 
1994). One explanation for this could be that Shiga toxin, al-
though normally traffi   cking in a Rab5-independent fashion, 
does pass through a Rab5-positive endocytic compartment, and 
this can also be perturbed by the overexpression of active mu-
tant forms of Rab5. In contrast, EGF traffi  cking is blocked by 
both RabGAP-5 and Rab5
Q79A (Figs. 2 and 6) and, therefore, 
does follow a Rab5-dependent pathway through early endo-
somes. Thus, dominant-active Rab5 appears to create a situa-
tion in which the function of the early endocytic pathway is 
perturbed such that molecules that normally traffi  c in a Rab5-
independent manner are also affected. Dominant-active Rabs 
should therefore be used with some caution, and, as shown here, 
Figure 7.  Biochemical screening for the target Rabs of speciﬁ  c TBC 
  domain proteins. To determine the speciﬁ  c activity toward a range of GTPases, 
0.5 pmol RN-tre, RabGAP-5, TBC1D10B, and TBC1D17 were tested against 
100 pmol of the Rab GTPases indicated using the procedures described in 
Materials and methods. All reactions were performed for 60 min. The basal 
GTP hydrolysis seen with a buffer control was subtracted for each GTPase, 
and the mean GTP hydrolysis in picomoles/hour is plotted in the ﬁ  gures. 
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specifi  c Rab GAPs provide valuable and specifi  c tools to 
manipulate the activity of endogenous Rabs.
Are Rab GAPs speciﬁ  c for particular 
Rab GTPases?
It has been suggested that Rab GAPs are not particularly spe-
cifi  c toward their target Rab (Albert and Gallwitz, 1999; Pan 
et al., 2006). However, this is somewhat counterintuitive because 
Rabs are argued to be important components acting at specifi  c 
membrane traffi  cking steps and for the specifi  cation of organelle 
identity (Pfeffer, 2001; Munro, 2002), and one would therefore 
expect their regulators to be equally specifi  c. We believe that 
Rab GAPs are likely to be specifi  c toward particular target Rabs 
or Rab subfamilies and have several arguments to support this 
statement. We show that GAPs such as TBC1D11/GAPCenA, 
RabGAP-5, and RN-tre are highly active toward specifi  c Rabs 
in biochemical assays. In addition, we can demonstrate that Rab 
GAPs have highly specifi  c effects on discrete membrane traf-
fi  cking pathways, which is consistent with the idea that they act 
on specifi  c Rabs in vivo.
A possible explanation for this discrepancy comes from 
our investigation of TBC1D11/GAPCenA, which was previ-
ously suggested to act on Rab6 (Cuif et al., 1999). In our 
hands, TBC1D11/GAPCenA acts on Rab4 but not Rab6 and 
does not have the effects on Rab6 effectors or Shiga toxin 
transport that is expected for a Rab6 GAP (Fig. 3). Investiga-
tion of the interaction between TBC1D11/GAPCenA and Rabs 
shows that regions outside of the minimal predicted catalytic 
domain are required for specifi  c Rab binding (Figs. 3 and S1). 
Strikingly, deletion of these regions relaxes the interaction 
specifi  city of the protein. Previous studies have used truncated 
GAP domains rather than full-length proteins (Albert and Gallwitz, 
1999; Pan et al., 2006), and, in light of our fi  ndings, this may be 
problematic because these proteins may have a relaxed specifi  city 
and, thus, may be able to accelerate GTP hydrolysis on a broader 
spectrum of Rabs. An analogous situation has been described for 
the GAP1 family of bifunctional Ras and Rap GAPs (Kupzig 
et al., 2006). In this case, regions outside of the core catalytic 
domain are required for the recognition of Rap (Kupzig et al., 
2006). Further investigation of Rab GAP specifi  city is needed 
before any general conclusions can be made, but it is clearly 
important to study the full-length proteins and not only the trun-
cated fragments corresponding to predicted domains.
Understanding Rab GAP function
There are >60 Rab family GTPases encoded by the human ge-
nome and at least 39 TBC domain–containing Rab GAPs. How-
ever, little is known about the function of the majority of these 
proteins. This is partly the result of the enormous complexity of 
membrane traffi  cking systems and the lack of suitable cell bio-
logical models for Rabs with functions in specifi  c tissues. As a 
fi  rst step in unravelling this complex network, we have screened 
for Rab GAPs that can infl  uence the traffi  cking of Shiga toxin 
to the Golgi or of EGF to early endosomes. Using biochemical 
assays, we have then identifi  ed target Rabs for several of these 
GAPs. This approach should be useful for the study of other traf-
fi  cking events, for traffi  cking between the ER and Golgi apparatus, 
or for a wide variety of different regulated secretory events.
Figure 8.  Functional veriﬁ  cation of the targets of RN-tre and 
RabGAP-5. (A–D) HeLa cells were transfected with siRNA du-
plexes to deplete all three isoforms of Rab5 (A and B) or 
Rab43 (C and D). (A and D) EGF uptake assays were per-
formed, and the extent of EGF transport at 30 min is shown 
in the ﬁ  gure. EGF is in green, and EEA1 is in red. (B and C) 
Shiga toxin uptake assays were performed, and the extent of 
STxB transport to the Golgi at 30 min is shown. STxB is in red, 
and GM130 is in green. (E) HeLa cells transfected with GFP-
tagged Rab43 (green) were ﬁ  xed after 24 h and stained with 
antibodies to the Golgi marker TGN46 or the early endo-
some marker EEA1 (red). DNA is stained blue in all panels. 
Bar, 10 μm.JCB • VOLUME 177 • NUMBER 6 • 2007  1142
Materials and methods
Antibody reagents
The antibody reagents used were as follows: mouse anti-GM130 and 
EEA1 (Becton Dickinson), sheep anti-TGN46 (Serotec), rabbit anti-Rab6 
(Santa Cruz Biotechnology, Inc.), and Bicaudal-D1 (Short et al., 2002). 
Donkey secondary antibodies conjugated to HRP, AMCA, CY2, and CY3 
were obtained from Jackson ImmunoResearch Laboratories.
Molecular biology and protein expression
The bacterial expression construct for STxB was provided by Y. Misumi 
(Fukuoka University School of Medicine, Fukuoka, Japan). Human Rab GAPs 
were identiﬁ  ed by searching the GenBank/EMBL/DDBJ database using 
the TBC domain signature motifs deﬁ  ned by Rak et al. (2000). The human 
Rab GAPs (EVI-5, RN-tre [USP6NL], RUTBC1, RUTBC2, RabGAP-5 [RUTBC3], 
TBC1D1, TBC1D2, TBC1D3B, TBC1D4, TBC1D5, TBC1D6, TBC1D7, 
TBC1D8, TBC1D10A, TBC1D10B, TBC1D10C, TBC1D11 [GAPCenA], 
TBC1D12, TBC1D13, TBC1D14, TBC1D15, TBC1D16, TBC1D17, 
TBC1D18, TBC1D19, TBC1D20, TBC1D21, TBC1D22A, TBC1D22B, 
USP6, AK074305, KIAA1055, KIAA0676, KIAA0882, NP_060222, 
NP_060779, EVI5-like, KIAA0984, and KIAA1171) were then ampliﬁ  ed 
from either human testis cDNA (Becton Dickinson) or HeLa cDNA using the 
pfu polymerase (Stratagene) and were cloned in pCRII-TOPO (Invitrogen). 
Point mutations were introduced using the QuikChange method (Stratagene). 
Constructs were conﬁ   rmed by DNA sequencing (Medigenomix; Max 
Planck Institute biochemistry sequencing core facility). Mammalian ex-
pression constructs were made in pcDNA3.1+ (Invitrogen) modiﬁ  ed to 
  encode a myc epitope tag and the pEGFP-C2 vector (CLONTECH Labora-
tories, Inc.). For yeast two-hybrid assays, Rabs were inserted into the bait 
vector pFBT9, pGBT9 (CLONTECH Laboratories, Inc.) was modiﬁ  ed  to 
carry kanamycin resistance, and Rab GAPs and mutants thereof were in-
serted into the prey vector pACT2 (CLONTECH Laboratories, Inc.). Yeast 
two-hybrid assays were performed according to the yeast protocol hand-
book (CLONTECH Laboratories, Inc.) as described previously (Haas et al., 
2005). Bacterial expression was performed using the T7 polymerase 
hexahistidine-GST expression vector pFAT2 for Rabs and the maltose-binding 
protein expression vector pMalC2 (New England Biolabs, Inc.) for Rab 
GAPs and the BL21(DE3) and JM109 strains, respectively. Fusion proteins 
were puriﬁ  ed over nickel-nitrilotriacetic acid agarose (QIAGEN) or amy-
lose resin (New England Biolabs, Inc.). Proteins were dialysed overnight 
against 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 2 mM DTT, and ali-
quots were frozen in liquid nitrogen for storage at –80°C.
GTP hydrolysis assays
For Rab-loading reactions, 10 μl of assay buffer, 73 μl H2O, 10 μl 10 mM 
EDTA, pH 8.0, 5 μl of 1 mM GTP, 2 μl γ-[
32P]GTP (10 mCi/ml; 5,000 Ci/
mmol; GE Healthcare), and 100 pmol Rab protein were mixed on ice. After 
15 min of incubation at 30°C, loaded Rabs were stored on ice. GTP binding 
was measured using a nitrocellulose ﬁ  lter-binding assay (Du and Novick, 
2001). GAP reactions were started by the addition of 0.5 pmol Rab GAP as 
speciﬁ  ed in the ﬁ  gures. A 2.5-μl aliquot of the assay mix was scintillation 
counted to measure the speciﬁ  c activity in counts per minute/picomole GTP. 
Reactions were then incubated at 30°C, taking 5-μl samples in duplicate at 
suitable time points as indicated in the ﬁ  gures. The 5-μl aliquots were imme-
diately added to 795 μl of ice-cold 5% [wt/vol] activated charcoal slurry in 
50 mM NaH2PO4, left for 1 h on ice, and centrifuged at 16,100 g in a 
benchtop microfuge (5417R; Eppendorf) to pellet the charcoal. A 400-μl ali-
quot of the supernatant was scintillation counted, and the amount of GTP hy-
drolyzed was calculated from the speciﬁ  c activity of the reaction mixture.
Cell culture and RNAi
HeLa cells were cultured at 37°C and 5% CO2 in growth medium (DME 
containing 10% FCS). HeLa cells plated on glass coverslips in a six-well 
plate at a density of 70,000 cells/well were used for plasmid transfection 
and at 25,000 cells/well for RNAi using conditions that were described 
previously (Haas et al., 2005). Rabs were targeted using siRNA duplexes 
obtained from Dharmacon. The sequences are listed in Fig. S5 B. For Western 
blotting, cells from three wells of a six-well plate were washed in 2 ml PBS 
and lysed in 70–80 μl of 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 
0.1% [wt/vol] Triton X-100. For each lane of a minigel, 10 μg of the pro-
tein lysate was loaded.
Shiga-like toxin cytotoxicity assays
Cytotoxicity was deﬁ  ned as a decrease in the ability of cells to incorpo-
rate [
35S]methionine into acid-precipitable material after Shiga-like toxin 1 
treatment using an established method (Spooner et al., 2004). HeLa cells were 
transiently transfected with either wild-type or RA mutant Rab GAPs for 9 h 
using Fugene-6 and the manufacturer’s protocol (Roche Diagnostics) and 
were replated in 96-well plates at a density of 1.5 × 10
4 cells/well and 
left for another 15 h. After washing with PBS, cells were incubated for 1 h 
with 100 μl DME/FCS containing serial twofold dilutions from 0.05–50 
ng/ml Shiga-like toxin 1. Subsequently, cells were washed with PBS and 
incubated in PBS containing 50 μCi/ml [
35S]methionine for 30 min. 
  Labeled proteins were precipitated with three washes in 5% [wt/vol] trichlo-
roacetic acid, the wells were washed twice with PBS, 50 μl of scintillation 
ﬂ  uid was added, and the amount of radiolabel incorporated was then de-
termined in a counter (MicroBeta 1450 TriLux; PerkinElmer). For each con-
dition, the IC50 for Shiga-like toxin 1 was calculated from the toxin titration 
performed in triplicate.
EGF uptake assays
EGF coupled to 200 μg/ml AlexaFluor488 or -555 (40× stock; Invitrogen) 
were stored as stock solutions in PBS at –20°C. For uptake assays, HeLa 
cells plated on glass coverslips at a density of 70,000 cells/well of a six-
well plate were washed three times with serum-free growth medium 36 h 
after plating and were incubated in serum-free growth medium for 15–16 h 
at 37°C and 5% CO2. Coverslips were then washed three times in ice-cold 
PBS and placed on 40-μl drops of uptake medium (DME, 2% [wt/vol] BSA, 
and 20 mM Hepes-NaOH, pH 7.5) and 5 μg/ml EGF on an ice-cold metal 
plate covered in Paraﬁ  lm (Pechiney Plastic Packaging). After 30 min of in-
cubation, the coverslips were washed three times in ice-cold PBS to remove 
excess ligand. One coverslip was ﬁ  xed to give the total bound ligand, 
whereas the remaining coverslips were transferred to a six-well plate con-
taining prewarmed growth medium and were incubated at 37°C and 5% 
CO2. At the time points indicated in the ﬁ  gures, coverslips were ﬁ  xed and 
processed for immunoﬂ  uorescence microscopy.
Preparation of STxB and uptake assays
Recombinant STxB was prepared as described previously (Johannes et al., 
1997; Sohda et al., 2005) and labeled on amine residues for 5 min 
at room temperature with an N-hydroxysuccinimidyl ester of Cy3 ac-
cording to the manufacturer’s instructions (GE Healthcare). These condi-
tions lead to a stoichiometry of ﬁ  ve Cy3 dye molecules per pentamer of 
STxB. The cell line and conditions used for uptake assays were the same 
as those described for EGF except that 0.7 μg/ml Cy3-STxB were used. 
For combined EGF and STxB assays, both proteins were mixed and 
bound simultaneously to the cell surface, and the standard procedure 
was followed.
Image acquisition
Cells to be imaged were ﬁ  xed for 20 min in 3% [wt/vol] PFA, quenched 
for 10 min with 50 mM ammonium chloride, and permeabilized with 0.1% 
[vol/vol] Triton X-100 for 5 min to allow labeling of internal cell structures. 
For cell surface labeling, cells were not permeabilized. All solutions were 
made in PBS, and antibody staining was performed for 60 min using a 
1,000-fold dilution of antiserum or puriﬁ  ed antibody at a ﬁ  nal concentra-
tion of 1 μg/ml. Coverslips were mounted in 10% [wt/vol] Moviol 4-88, 
1 μg/ml DAPI, and 25% [wt/vol] glycerol in PBS. Images were collected at 
a room temperature of 22°C using a microscope (Axioskop-2; Carl Zeiss 
MicroImaging, Inc.) with a 63× plan Apochromat oil immersion objective 
(Carl Zeiss MicroImaging, Inc.) of NA 1.4, standard ﬁ  lter sets (Carl Zeiss 
MicroImaging, Inc.), a 1,300 × 1,030-pixel cooled CCD camera (CCD-
1300-Y; Princeton Instruments), and Metavue software (Visitron Systems). 
Images were cropped in Photoshop 7.0 (Adobe) or CS2 software (Adobe) 
without contrast or other adjustments, sized, and placed using Illustrator 
11.0 (Adobe) or CS2.
Online supplemental material
Fig. S1 shows that the interaction speciﬁ  city of TBC1D11/GAPCenA with 
human Rab GTPases involves regions outside of the TBC domain. Fig. S2 
shows the effect of Rab GAPs blocking Shiga toxin uptake on Golgi 
morphology. Fig. S3 shows the effect of Rab GAPs blocking Shiga toxin 
uptake on the Rab6 effector Bicaudal-D1. Fig. S4 shows that RabGAP-5 
interacts with Rab5A-C but not other Rabs. Fig. S5 shows the speciﬁ  c deple-
tion of target Rabs using RNAi. Online supplemental material is available 
at http://www.jcb.org/cgi/content/full/jcb.200612068/DC1.
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